Butyrylcholinesterase: Association with the metabolic syndrome and identification of 2 gene loci affecting activity

Clinical Chemistry

Volumn 52, Issue 6, 2006, Pages 1014-1020

  Valle, Anne ^a   O'Connor, Daniel T ^a,b   Taylor, Palmer ^a   Zhu, Gu ^c   Montgomery, Grant W ^c   Slagboom, P Eline ^d   Martin, Nicholas G ^c   Whitfield, John B ^c,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; APOLIPOPROTEIN E; ASPARTATE AMINOTRANSFERASE; CHOLINESTERASE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; URATE;

ARTICLE; BCHE GENE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 3; CHROMOSOME 5; CONTROLLED STUDY; CORRELATION ANALYSIS; DIZYGOTIC TWINS; ENZYME ACTIVITY; FEMALE; GENE; GENE ACTIVITY; GENE IDENTIFICATION; GENE LOCUS; GENETIC VARIABILITY; HEREDITY; HUMAN; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; QUANTITATIVE TRAIT LOCUS; RUST (PLANT DISEASE); STRUCTURAL GENE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BUTYRYLCHOLINESTERASE; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LINKAGE (GENETICS); MALE; METABOLIC SYNDROME X; MIDDLE AGED; QUANTITATIVE TRAIT, HERITABLE; RISK FACTORS; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC;

EID: 33646903923     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2005.065052     Document Type: Article

References (42)

1. Evans FT, Gray PW, Lehmann H, Silk E. Sensitivity to succinylcholine in relation to serum cholinesterase. Lancet 1952;1:1229-30.
2. Harris H. Enzymes and drug sensitivity. The genetics of serum cholinesterase 'deficiency' in relation to suxamethonium apnoea. Proc R Soc Med 1964;57:503-6.
3. Yen T, Nightingale BN, Burns JC, Sullivan DR, Stewart PM. Butyrylcholinesterase (BCHE) genotyping for post-succinylcholine apnea in an Australian population. Clin Chem 2003;49:1297-308.
4. George ST, Varghese M, John L, Balasubramanian AS. Aryl acylamidase activity in human erythrocyte, plasma and blood in pesticide (organophosphates and carbamates) poisoning. Clin Chim Acta 1985;145:1-7.
5. Abbott CA, Mackness MI, Kumar S, Olukoga AO, Gordon C, Arrol S, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci (Lond) 1993;85:77-81.
6. Alcantara VM, Oliveira LC, Rea RR, Suplicy HL, Chautard-Freire-Maia EA. Butyrylcholinesterase activity and metabolic syndrome in obese patients. Clin Chem Lab Med 2005;43:285-8.
7. Annapurna V, Senciall I, Davis AJ, Kutty KM. Relationship between serum pseudocholinesterase and triglycerides in experimentally induced diabetes mellitus in rats. Diabetologia 1991;34:320-4.
8. Kutty KM, Payne RH. Serum pseudocholinesterase and very-low-density lipoprotein metabolism. J Clin Lab Anal 1994;8:247-50.
9. Rustemeijer C, Schouten JA, Voerman HJ, Beynen AC, Donker AJ, Heine RJ. Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in type II diabetes mellitus? Clin Sci (Lond) 2001;101:29-35.
10. Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G. Relationship between serum butyrylcholinesterase and the metabolic syndrome. Clin Biochem 2005;38:799-805.
11. Hashim Y, Shepherd D, Wiltshire S, Holman RR, Levy JC, Clark A, et al. Butyrylcholinesterase K variant on chromosome 3q is associated with type II diabetes in white Caucasian subjects. Diabetologia 2001;44:2227-30.
12. Johansen A, Nielsen EM, Andersen G, Hamid YH, Jensen DP, Glumer C, et al. Largescale studies of the functional K variant of the butyrylcholinesterase gene in relation to type 2 diabetes and insulin secretion. Diabetologia 2004;47:1437-41.
13. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997;6:1933-6.
14. Panegyres PK, Mamotte CD, Vasikaran SD, Wilton S, Fabian V, Kakulas BA. Butyrylcholinesterase K variant and Alzheimer's disease. J Neurol 1999;246:369-70.
15. Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999;104:158-63.
16. McIlroy SP, Crawford VL, Dynan KB, McGleenon BM, Vahidassr MD, Lawson JT, et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet 2000;37:182-5.
17. Ghebremedhin E, Thal DR, Schultz C, Braak H. Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains. Neurosci Lett 2002;320:25-8.
18. Crawford F, Fallin D, Suo Z, Abdullah L, Gold M, Gauntlett A, et al. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations. Neurosci Lett 1998;249:115-8.
19. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG, et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet 1998;7:937-9.
20. Yamamoto Y, Yasuda M, Mori E, Maeda K. Failure to confirm a synergistic effect between the K-variant of the butyrylcholinesterase gene and the epsilon4 allele of the apolipoprotein gene in Japanese patients with Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;67:94-6.
21. Online Mendelian Inheritance in Man. Butyrylcholinesterase; BCHE. OMIM 177400. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=177400 (accessed March 28, 2006).
22. Steegmuller H. On the geographical distribution of pseudocholinesterase variants. Humangenetik 1975;26:167-85.
23. Online Mendelian Inheritance in Man. Cholinesterase, serum, 2; CHE2. OMIM 177500. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=177500 (accessed March 28, 2006).
24. Akizuki S, Ohnishi A, Kotani K, Sudo K. Genetic and immunological analyses of patients with increased serum butyrylcholinesterase activity and its C5 variant form. Clin Chem Lab Med 2004;42:991-6.
25. Whitfield JB, Fletcher LM, Murphy TL, Powell LW, Halliday J, Heath AC, et al. Smoking, obesity, and hypertension alter the dose-response curve and test sensitivity of carbohydrate-deficient transferrin as a marker of alcohol intake. Clin Chem 1998;44:2480-9.
26. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-95.
27. Neale MC. Mx: Statistical Modeling, 5th ed. Department of Psychiatry. Richmond, VA: Medical College of Virginia, 1999.
28. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
29. Beekman M, Heijmans BT, Martin NG, Pedersen NL, Whitfield JB, DeFaire U, et al. Heritabilities of apolipoprotein and lipid levels in three countries. Twin Res 2002;5:87-97.
30. Nyholt DR, Morley KI, Ferreira MA, Medland SE, Boomsma DI, Heath AC, et al. Genomewide significant linkage to migrainous headache on chromosome 5q21. Am J Hum Genet 2005;77:500-12.
31. Abecasis GR, Burt RA, Hall D, Bochum S, Doheny KF, Lundy SL, et al. Genomewide scan in families with schizophrenia from the founder population of Afrikaners reveals evidence for linkage and uniparental disomy on chromosome 1. Am J Hum Genet 2004;74:403-17.
32. Lander E, Kruglyak L Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet 1995;11:241-7.
33. Shete S, Beasley TM, Etzel CJ, Fernandez JR, Chen J, Allison DB, et al. Effect of winsorization on power and type 1 error of variance components and related methods of QTL detection. Behav Genet 2004;34:153-9.
34. Whitby LG, Mitchell FL, Moss DW. Quality control in routine clinical chemistry. Adv Clin Chem 1967;10:65-156.
35. Thamer C, Tschritter O, Haap M, Shirkavand F, Machann J, Fritsche A, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intrahepatic lipids. Horm Metab Res 2005;37:246-51.
36. Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA. γ-Glutamyl transpeptidase and the metabolic syndrome. J Intern Med 2000;248:230-8.
37. Kutty KM, Huang SN, Kean KT. Pseudocholinesterase in obesity: hypercaloric diet induced changes in experimental obese mice. Experientia 1981;37:1141-2.
38. Popescu TA, Fekete T, Popescu E, Bojthy I, Laszlo M. Serum pseudocholinesterase activity during experimental fattening. Med Interne 1976;14:71-3.
39. Higashi Y, Yoshizumi M. New methods to evaluate endothelial function: method for assessing endothelial function in humans using a strain-gauge plethysmography: nitric oxide-dependent and -independent vasodilation. J Pharmacol Sci 2003;93:399-404.
40. Olswold C, de Andrade M. Localization of genes involved in the metabolic syndrome using multivariate linkage analysis. BMC Genet 2003;4(Suppl 1):S57.
41. McQueen MB, Bertram L, Rimm EB, Blacker D, Santangelo SL. A QTL genome scan of the metabolic syndrome and its component traits. BMC Genet 2003;4(Suppl 1):S96.
42. Heijmans BT, Beekman M, Putter H, Lakenberg N, van der Wijk HJ, Whitfield JB, et al. Meta-analysis of four new genome scans for lipid parameters and analysis of positional candidates in positive linkage regions. Eur J Hum Genet 2005;13:1143-53.